TWD 744.0
(-0.67%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 1.95 Billion TWD | -54.68% |
2022 | 4.31 Billion TWD | 227.97% |
2021 | 1.31 Billion TWD | -40.5% |
2020 | 2.21 Billion TWD | 131.26% |
2019 | 956.63 Million TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | 996.08 Million TWD | -49.09% |
2024 Q2 | 13.11 Billion TWD | 1216.83% |
2023 Q4 | 1.95 Billion TWD | -27.0% |
2023 Q2 | 2.35 Billion TWD | 24.79% |
2023 Q1 | 1.89 Billion TWD | -55.41% |
2023 FY | 1.95 Billion TWD | -54.68% |
2023 Q3 | 2.68 Billion TWD | 13.64% |
2022 Q3 | 5.41 Billion TWD | 0.0% |
2022 Q4 | 4.23 Billion TWD | -21.78% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Grape King Bio Ltd | -4.62 Billion TWD | 142.297% |
Standard Chem & Pharm CO., LTD. | -954.74 Million TWD | 304.93% |
Maywufa Company Ltd. | 264.18 Million TWD | -640.6% |
ScinoPharm Taiwan, Ltd. | -3.32 Billion TWD | 158.925% |
Lotus Pharmaceutical Co., Ltd. | 9.81 Billion TWD | 80.063% |
LIWANLI Innovation Co., Ltd. | -244.02 Million TWD | 901.791% |
YungShin Global Holding Corporation | -247.5 Million TWD | 890.524% |
PhytoHealth Corporation | -34.64 Million TWD | 5748.088% |
SCI Pharmtech, Inc. | 100.41 Million TWD | -1848.429% |
Formosa Laboratories, Inc. | 2.53 Billion TWD | 22.922% |
PharmaEssentia Corporation | -18.46 Billion TWD | 110.596% |